Combination therapy of cancer using statinib and KRAS g12c inhibitors

What is AI technical title?
AI technical title is built by Patsnap AI team. It summarizes the technical point description of the patent document.
The combination therapy of zogerinib and a KRAS G12C inhibitor synergistically inhibits HER2 and KRAS G12C, addressing the inadequacy of existing therapies and achieving effective treatment and tumor shrinkage for HER2-dependent and KRAS G12C-mutant cancers.

CN122458993APending Publication Date: 2026-07-24BOEHRINGER INGELHEIM INT GMBH

10 Cites 0 Cited by

Patent Information

Application Number: CN202480081404.X
Authority / Receiving Office: CN · China
Patent Type: Applications(China)
Current Assignee / Owner
Priority Date: 2024-07-12
Filing Date: 2024-12-18
Publication Date: 2026-07-24

Application Information

Patent Timeline

12 Jul 2024

Priority

18 Dec 2024

Application

CN202480081404.X

24 Jul 2026

Publication

CN122458993A

IPC: A61K31/519; A61P35/00

CPC: A61K31/519; A61P35/00; A61K2300/00

Get more patent work done with AI

Run novelty searches—or use them for FTO, design risk, drafting and technical problem-solving.

AI Tagging

Application Domain

Organic active ingredients Antineoplastic agents

Technology Topics

Disease KRAS

Explore More Agents

Novelty Search
Search existing technologies and assess novelty
↗
FTO
Analyze whether a product may infringe others' patents
↗
Design FTO
Check prior-design risk for exterior design
↗
Drafting
Draft patent application text based on a technical solution
↗
Find Solutions with TRIZ
Generate feasible solution to solve your technical challenge
↗
IP MCP Servers
Connect trusted patent search and cited evidence to Claude, Cursor or your own AI workflow
↗

AI Technical Summary

Technical Problem

Existing treatments have limited efficacy against HER2-dependent cancers and KRAS G12C-mutant cancers, and targeted therapies for KRAS mutants have resistance issues, necessitating more effective combination therapy regimens.

Method used

Zongetinib, when used in combination with KRAS G12C inhibitors (such as sotoraraxib or adagraxib), inhibits HER2 tyrosine kinase and KRAS G12C through combination therapy, achieving synergistic anti-proliferative activity and enhancing the efficacy of KRAS inhibitors.

Benefits of technology

It demonstrated synergistic effects in cancer treatment, achieving tumor shrinkage and tolerability, expanding the patient population that benefits from KRAS G12C inhibitors, and had no significant toxicity.

✦ Generated by Eureka AI based on patent content.

Patent Text Reader

Abstract

The present invention relates to a combination of a HER2 tyrosine kinase zongertinib (zongertinib) and a KRAS G12C inhibitor. The present invention also relates to a method for preparing the same. The combinations of the invention are useful in the treatment and / or prevention of oncogenic and / or hyperproliferative diseases, such as cancer. Thus, provided herein are compounds used in relation to the combination, methods of prevention and / or treatment, uses, pharmaceutical compositions, and kits.

Need to check novelty before this filing date? Find Prior Art